Related Experiment Video
Updated: Apr 26, 2026

Intracerebroventricular Delivery of Gut-Derived Microbial Metabolites in Freely Moving Mice
Published on: June 2, 2022
Pharmacological, Pharmacokinetic, and Pharmacogenomic Aspects of Disorders of Gut-Brain Interaction
Michael Camilleri1, Giovanni Sarnelli2, Viola Andresen3
1Mayo Clinic, Rochester, Minnesota.
Abstract:
We conducted a literature review of preclinical, animal and human pharmacology, pharmacokinetics, and pharmacogenomics related to disorders of gut-brain interaction (DGBI). This article reviews animal models of visceral pain, abnormal motility, and epithelial transport, and human models of motility and sensation and their utility in drug development for DGBI with focus on colorectal and gastric biomarkers. We highlight preclinical studies related to pharmacology, pharmacokinetics, and toxicology required for development of novel therapeutic agents, and principles of pharmacogenomics based on drug metabolism and the few examples of pharmacogenetics related to targets in treatment of IBS. Finally, we summarize the human pharmacology of medications used for treatment of DGBI based on the individual indications - specifically psychopharmacologic and nonpsychotropic agents for DGBI associated with dyspepsia, constipation, diarrhea, and visceral pain, as well as introduction of biomarkers for individualizing therapy for IBS and recommendations for future research.
Related Concept Videos
Gut-Brain Axis
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics of Drug Metabolism: Overview
Factors Influencing Drug Absorption: Disease States and Pharmacology
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
Pharmacogenomics: Identification of New Drug Targets

